FDAnews Drug Daily Bulletin
Oct. 9, 2012 | Vol. 9 No. 198
Pharma Blog Watch
In a Snap, Trying to Discontinue Cymbalta (Pharmalot blog)
“There has always been concern about discontinuing antidepressants and withdrawal symptoms,” blogger Ed Silverman writes. A new study shows between 40 to 50 percent of Cymbalta (duloxetine) experienced withdrawal symptoms after clinical trials, and more than half were resolved within two weeks, Silverman adds. The analysis was conducted after a review of adverse events reported during the 2012 first quarter Institute for Safe Medicine Practices found 48 cases of Cymbalta withdrawal including blackouts, suicidal thoughts, tremor and nausea. “This contrasted with an FDA safety review conducted in 2001 for the Cymbalta new drug application,” Silverman writes.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.